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Purpose
Treatment options for neuroendocrine tumors (NETs) remain limited. This trial assessed the
progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-a-2b) added to octreotide
among patients with advanced NETs.
Patients and Methods
Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group
system, enrolled patients with advanced grades 1 and 2 NETs with progressive disease or other poor
prognostic features. Patients were randomly assigned to treatment with octreotide LAR 20 mg
every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-a-2b three
times per week. The primary end point was centrally assessed PFS. This trial is registered with
ClinicalTrials.gov as NCT00569127.
Results
A total of 427 patients was enrolled, of whom 214 were allocated to bevacizumab and 213 to IFNa-2b. The median PFS by central review was 16.6 months (95% CI, 12.9 to 19.6 months) in the
bevacizumab arm and was 15.4 months (95% CI, 9.6 to 18.6 months) in the IFN arm (hazard ratio
[HR], 0.93; 95% CI, 0.73 to 1.18; P = .55). By site review, the median PFS times were 15.4 months
(95% CI, 12.6 to 17.2 months) for bevacizumab and 10.6 months (95% CI, 8.5 to 14.4 months) for
interferon (HR, 0.90; 95% CI, 0.72 to 1.12; P = .33). Time to treatment failure was longer with
bevacizumab than with IFN (HR, 0.72; 95% CI, 0.58 to 0.89; P = .003). Conﬁrmed radiologic response rates were 12% (95% CI, 8% to 18%) for bevacizumab and 4% (95% CI, 2% to 8%) for IFN.
Common adverse events with bevacizumab and octreotide included hypertension (32%), proteinuria
(9%), and fatigue (7%); with IFN and octreotide, they included fatigue (27%), neutropenia (12%), and
nausea (6%).
Conclusion
No signiﬁcant differences in PFS were observed between the bevacizumab and IFN arms, which
suggests that these agents have similar antitumor activity among patients with advanced NETs.
J Clin Oncol 35:1695-1703. © 2017 by American Society of Clinical Oncology
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Neuroendocrine tumors (NETs), though once
thought rare, have experienced an increased incidence.1 Their clinical course is often indolent
but also can be highly aggressive and resistant to
therapy. Despite the approval of targeted agents,
everolimus and sunitinib, for pancreatic NETs,2,3
there remains tremendous unmet need in NETs of

other sites, previously called carcinoid tumors.
Although lanreotide delays progression compared
with placebo in indolent gastroenteropancreatic
NETs with less than 10% Ki-67 labeling, and
everolimus delays progression in progressive
NETs that develop in the lung and gastrointestinal
tract, additional treatment options are needed.4,5
Well-differentiated NETs are highly vascular
tumors. Vascular endothelial growth factor
(VEGF) expression has been demonstrated in
© 2017 by American Society of Clinical Oncology
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both gastrointestinal and pulmonary NETs and is associated with
poor outcome.6-8 In a phase II study of octreotide plus bevacizumab
versus octreotide plus pegylated interferon alpha, bevacizumab
therapy was associated with a rapid decrease in tumor perfusion,
a higher response rate, and a longer progression-free survival (PFS)
compared with low-dose pegylated interferon.9 Subsequently, several smaller phase II studies of bevacizumab in combination with
capecitabine, everolimus, temsirolimus, or temozolomide demonstrated promising activity in NETs.10-14
Interferon alfa has been widely studied and used in NET. In
one meta-analysis of published studies, 37 (12%) of 309 treated
patients experienced an objective response.15 The value of combined interferon and octreotide was tested in a randomized study
in which patients with NETs who had undergone debulking by
surgery and hepatic artery embolization were randomly assigned to
octreotide or octreotide plus interferon. A signiﬁcant improvement
in time to progression was observed in the interferon arm (hazard
ratio [HR], 0.28; 95% CI, 0.16 to 0.45).16 Though controversy
remains about the utility of interferon, octreotide plus interferon
was considered an accepted systemic therapy option by the National Comprehensive Cancer Network at the time of this study
design in 2005.17
Southwest Oncology Group (SWOG) S0518 was conducted to
determine whether depot octreotide plus bevacizumab prolongs
PFS compared with depot octreotide plus interferon alfa-2b in
patients with advanced, poor-prognosis NET.

All authors contributed to the interpretation of data and the subsequent writing, reviewing, and/or amending of the manuscript; the ﬁrst
draft of the manuscript was prepared by the ﬁrst author (J.C.Y.) and SWOG
statisticians (K.A.G., S.M.). All authors vouched for the accuracy and
completeness of the data and attested that the study conformed to the
protocol and analysis plan.

Random Assignment
In this open-label, phase III study, patients were randomly assigned in
a 1:1 manner into the two treatment groups by using a dynamic balancing
algorithm by Pocock and Simon,19 with stratiﬁcation on the basis of
primary site (small bowel, cecum, appendix [midgut] v other), progressive
disease (radiologic report within 6 months of registration that documented
progressive disease), grade (1 v 2), and prior octreotide (treatment within
2 months before registration v none within 2 months).
Treatment Plan
After random assignment, all patients received depot octreotide
20 mg intramuscularly on day 1 of each 21-day cycle. This dosing regimen
of octreotide LAR delivered approximately the same dose of octreotide
(0.95 mg/day) as the 30-mg monthly regimen used in the PROMID
study.20 In arm 1, patients received bevacizumab 15 mg/kg intravenously
on day 1; in arm 2, they received 5 million units of interferon alfa-2b three
times per week as a subcutaneous injection. A maximal delay of 4 weeks
was allowed for safety. No dose reduction was allowed in the bevacizumab
arm. In the interferon arm, the protocol permitted, at the discretion of the
treating investigator, a 1-week treatment break from interferon alfa every
6 weeks. Sequential dose reduction for neutropenia or clinically signiﬁcant
grade 3 or 4 adverse events to 3, 2, or 1 million units three times per week
was allowed per protocol in the interferon arm.

PATIENTS AND METHODS
Patients
Adult patients (age $ 18 years) with pathologically conﬁrmed, advanced (unresectable or metastatic), grade 1 or grade 2 NET were eligible
for participation. Patients must have had one of the following poorprognosis features: (1) progressive disease; (2) refractory carcinoid syndrome; (3) grade 2 histology and more than six sites of metastasis1,18; (4)
metastatic hindgut NET1; or (5) metastatic gastric NET.1
Additional key inclusion criteria included measurable disease
according to Response Evaluation Criteria in Solid Tumors (RECIST),
version 1.0; Zubrod performance status of 0, 1, or 2; and adequate bone
marrow, liver, and kidney function. The urine protein creatinine ratio had
to be 0.5 or less, or the 24-hour urine protein had to be less than 1,000 mg,
for patient enrollment. Patients with a history of hypertension must have
had controlled blood pressure (, 150/90 mmHg) and been on a stable
regimen of antihypertensive therapy. One prior regimen of cytotoxic chemotherapy or targeted therapy, excluding VEGF inhibitors, was allowed.
Prior surgery, liver directed therapy, and radiotherapy were allowed if
completed more than 28 days before the start of study therapy, the patient
had recovered from the procedure, and there were residual sites of measurable disease. Prior depot octreotide was allowed provided at least 21 days
had elapsed since the last dose until the start of study therapy.
Study Oversight
The study was conducted in accordance with Good Clinical Practice,
ethical principles of the Declaration of Helsinki, and local regulations. The
Cancer Trials Support Unit central institutional review board and local
institutional review board at participating centers reviewed and approved
the study and all the amendments. All patients provided written informed
consent. The SWOG independent Data and Safety Monitoring Committee
provided ongoing oversight of safety and study conduct. This trial was
registered with ClinicalTrials.gov, number NCT00569127.
1696
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Study Assessments
The primary study end point of PFS from random assignment was
assessed independently and centrally (but case-level results were not shared
in real-time with sites) according to RECIST 1.0. In both arms, tumor
measurements were made by multiphasic computed tomography (CT)
scans or magnetic resonance imaging (MRI) at baseline and every 9 weeks.
Central radiology review, blinded to treatment assignment, was performed
by the American College of Radiology Imaging Network.
A retrospective central pathology review was conducted by an experienced NET pathologist (C.M.). Adequate tumor tissue was assessed in
341 patient cases (80%). Differentiation and grade, determined by mitotic
rate, were determined and classiﬁed.
Adverse events (AEs) were assessed as per National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
All patients who received at least one dose of the study drug and had at least
one postbaseline safety evaluation were included in the safety analyses.
Sites were required to report only AEs of grade 3 or higher.
Biomarkers
Baseline blood chromogranin A (CGA), neuron-speciﬁc enolase
(NSE), and 24-hour urinary 5-hydroxyindoleacetic acid (5HIAA) were
collected and assayed per standard medical practice in a commercial
laboratory used by participating sites. Baseline CGA was considered elevated if it was greater than twice upper limit of normal.2,5,21,22 5HIAA and
NSE were considered elevated if they were greater than the laboratory
upper limit of normal. Additional exploratory biomarkers, including somatostatin receptor scintigraphy as well as blood- and tissue- based assessment of angiogenic biomarkers, are planned.
Outcomes
The primary outcome, PFS according to central radiology review, was
deﬁned as one of the following events: documented progression of lesions
JOURNAL OF CLINICAL ONCOLOGY
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on the basis of centrally reviewed scans, new lesion formation, symptomatic deterioration (as documented by the institution), or death. Patients were censored at the time of the last scan that was centrally reviewed
and did not show progression.
Secondary outcomes included site-reported PFS, overall survival
(OS), time to treatment failure (TTF), objective response (conﬁrmed and
unconﬁrmed complete response and partial response), and toxicity. TTF
criteria included central review–based progression of lesions, symptomatic
deterioration, death, or discontinuation of treatment as events; censoring
was deﬁned as for the primary outcome. For site-reported PFS and OS,
censoring time was deﬁned as the date of last contact. All time-to-event end
points were measured from the time of random assignment. Patients were
observed until death or 3 years after registration, whichever occurred ﬁrst.

Statistical Considerations
At the time of the trial design, little information was available about
PFS of NETs on the basis of large prospective clinical trials that used
RECIST. On the basis of available information, it was estimated that the
median PFS in the octreotide-plus-interferon group of patients was
6 months, and that an improvement of 50% (HR of 0.67, which corresponded to a median PFS of 9 months) would be of clinical interest. Before
the ﬁrst interim analysis, the event rate was lower than originally hypothesized and was more consistent with approximately 15 months. Thus,
the originally proposed HR of 0.67 would correspond to a median of
22.5 months, a difference of 7.5 months. It was determined that an HR of
0.71 (which corresponded to a median of 21 months) would be of sufﬁcient clinical interest. If an additional year of accrual (from 3 to 4 years)
was assumed, and a total of 2 years of follow-up was required after the end
of accrual, 400 eligible patients would provide 84% power to detect a 0.71
HR on the basis of a two-sided .05-level test.
According to the intent-to-treat principle, all eligible patients were
included in the analyses according to the randomized treatment assignment, regardless of actual treatments received. Probabilities of OS, PFS,
and TTF were estimated by using the Kaplan-Meier method. Statistical
differences in event rates between treatment arms were assessed via
stratiﬁed Cox regression model. Disease response was described by waterfall plots, separately by treatment arm, and rates of objective response
were compared via the x2 test in the subset of patients with measurable
disease. Statistical differences in central radiology review of PFS and OS
event rates between groups according to elevated versus normal levels of
potential biomarkers (CGA, NSE, and 5HIAA) were assessed via the Cox

Randomly assigned (N = 427)

Assigned
to bevacizumab plus octreotide
(n = 214)
Ineligible

Eligible

(n = 14)

(n = 200)

Discontinued
(n = 193)
Disease progression
(n = 99)
Adverse event
(n = 57)
Withdrawal of consent (n = 13)
Death
(n = 4)
Other/unknown
(n = 20)

Remained on treatment

(n = 7)

Assigned
to interferon plus octreotide
(n = 213)

Ineligible

Eligible

(n = 11)

(n = 202)

(n = 199)
Discontinued
Disease progression (n = 100)
Adverse event
(n = 47)
Withdrawal of consent (n = 27)
Death
(n = 3)
Other/unknown
(n = 22)

Remained on treatment

(n = 3)

regression model. The following factors were considered as potential PFS
treatment effect modiﬁers: midgut versus nonmidgut disease, grade 1
versus 2 disease, Zubrod performance status of 0 versus 1 or 2, and normal
versus elevated CGA, NSE, and 5HIAA levels. Tests for interaction between
these variables and treatment assignment were performed within the Cox

Table 1. Patient Characteristics
No. (%) of Patients

Characteristic
Median (range) age, years
Sex
Male
Female
Zubrod PS
0
1
2
Site
Small bowel, cecum,
appendix
Other
PD since diagnosis
Refractory carcinoid
syndrome
Histologic grade
1
2
Site of involvement
Liver
Distant lymph nodes
Bone
Other abdominal
Other
Biomarker
CGA . 23 ULN
NSE . ULN
5HIAA . ULN
Prior therapy
Octreotide within
2 months
Radiation therapy
Chemotherapy
Central pathology review
Differentiation
Well differentiated
Moderately
differentiated
Poorly differentiated
Grade
1
2
3
Mitotic rate, per 10
HPF†
, 2 (grade 1)
2-20 (grade 2)
. 20 (grade 3)

Bevacizumab +
Octreotide LAR
(n = 200*)

IFN-a-2b +
Octreotide LAR
(n = 202*)

61 (27-85)

61 (23-85)

102 (51)
98 (49)

90 (45)
112 (55)

107 (54)
88 (44)
5 (3)

99 (49)
98 (49)
4 (2)

71 (35)

72 (36)

129 (64)
182 (91)
16/184 (9)

130 (64)
188 (93)
21/187 (11)

169 (84)
31 (15)

171 (85)
31 (15)

172
47
38
43
50

173
43
34
44
51

(86)
(24)
(19)
(22)
(25)

(86)
(21)
(17)
(22)
(25)

124/197 (63)
62/195 (32)
127/193 (66)

117/196 (60)
64/189 (34)
113/191 (59)

114 (57)

115 (57)

67 (34)
56 (28)

62 (31)
50 (25)

140 (83)
25 (15)

144 (83)
28 (16)

3 (2)

1 (1)

141 (84)
24 (14)
3 (2)

144 (83)
28 (16)
1 (1)

81/111 (73)
29/111 (26)
1/111 (1)

95/122 (78)
27/122 (22)
0/122 (0)

NOTE. Total No. of patients are listed in table cells when they differ from the
group totals.
Abbreviations: 5HIAA, 5-hydroxyindoleacetic acid; CGA, chromogranin A; HPF,
high-powered ﬁeld; IFN-a-2b, interferon alfa-2b; LAR, long-acting repeatable;
NSE, neuron-speciﬁc enolase; PD, progressive disease; PS, performance status;
ULN, upper limit of normal.
*No. of patients assessed for central pathology review: n = 168 in bevacizumab
arm; n = 173 in IFN-a-2b arm.
†Mitotic rate determined when adequate tumor material that contained at least
10 HPF were available.

Fig 1. CONSORT diagram.
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regression model. The strength of associations between patient characteristics and treatment assignment were tested via the t or x2 test. All
P values were two sided.

RESULTS

Between December 2007 and September 2012, 427 patients with
advanced, well-differentiated, grade 1 or 2 NETs with progressive
disease or other poor prognostic features were randomly assigned
(1:1) to the treatment arms (Fig 1). Four hundred two patients
were eligible and included in the efﬁcacy analyses. The baseline
characteristics of patients were balanced across arms (Table 1).
Most patients had good performance statuses. In the bevacizumab and interferon arms, 54% and 49% of the patients,
respectively, had a performance status of zero. Midgut was the
most common primary site; 35% and 36% of the patients in the

PFS
No signiﬁcant differences were observed in the primary end
point, PFS by blinded central radiology review (Fig 2A). The
median PFS assessed by central review was 16.6 months (95%
CI, 12.9 to 19.6 months) in the bevacizumab arm and was

B
1.0

0.8

Treatment arm (No./total No.)

Median PFS (months)

Bevacizumab (n = 142/200)

16.6 (95% CI, 12.9 to 19.6)

Interferon (n = 165/202)

15.4 (95% CI, 9.6 to 18.6)

HR, 0.93; 95% CI, 0.73 to 1.18; P = .55

0.6

0.4

0.2

0

6

12

18

24

30

Progression-Free Survival (probability)

Progression-Free Survival (probability)

A

bevacizumab and interferon arms, respectively, had small bowel,
cecum, or appendix as primary sites. Radiologic disease progression
was documented in 91% and 93% of patients in the bevacizumab
and interferon arms, respectively. More than half of the patients in
each arm were receiving octreotide at the time of study entry.
At the time of ﬁnal analysis, 10 patients were still taking study
treatment. In the bevacizumab and interferon arms, 193 and 199
patients, respectively, discontinued protocol treatment. Common
reasons for treatment discontinuation included disease progression, AEs, and withdrawal of consent (Fig 1).

36

1.0

Treatment arm (No./total No.) Median PFS (months)

0.8

Bevacizumab (n = 165/200)

15.4 (95% CI, 12.6 to 17.2)

Interferon (n = 162/202)

10.6 (95% CI, 8.5 to 14.4)

HR, 0.90; 95% CI, 0.72 to 1.12; P = .33

0.6

0.4

0.2

0

6

12

Time (months)

C

24

30

36

D
1.0

1.0

0.8

0.8

Treatment arm (No./total No.)

Median TTF (months)

Bevacizumab (n = 181/200)

9.9 (95% CI, 7.3 to 11.1)

Interferon (n = 179/202)

5.6 (95% CI, 4.3 to 6.4)

HR, 0.72; 95% CI, 0.58 to 0.89; P = .003

Proportion

Overall Survival (probability)

18

Time (months)

0.6

0.4

0.6

0.4

Treatment arm (No./total No.) Median OS (months)

0.2

Bevacizumab (n = 109/200)

35.2 (95% CI, 33.1 to 42.8)

Interferon (n = 94/202)

Not reached

0.2

HR, 1.16; 95% CI, 0.88 to 1.55; P = .29

0

6

12

18

24

Time (months)

30

36

0

6

12

18

24

30

36

Time (months)

Fig 2. Survival plots by treatment arm: (A) central-review progression-free survival (PFS); (B) site-review (investigator-reviewed) PFS; (C) overall survival; (D) time to
treatment failure.
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Fig 3. Waterfall plots: (A) bevacizumab;
(B) interferon. The bars on each plot represent the largest decrease under baseline
of the sum of longest diameters of all
target measurable lesions or, if no decrease was observed, the smallest increase in the sum of longest diameters of
target measurable lesions. Patients in
whom the smallest increase in measurable
lesions was greater than 100% over
baseline had data truncated at 100%. Data
for patients in whom the best response
was progression because of new lesions,
death (as a result of disease), or clear
worsening of nonmeasurable disease are
represented by a bar that shows a 100%
increase. Data for patients in whom the
best response could not be determined
because of symptomatic deterioration or
early death (before any follow-up assessments and clearly not as a result of disease)
are represented by a gray bar showing 100%
increase. Data for patients in whom the best
response could not be determined because
of inadequate assessment are represented
on the far-left side of the plot with a blue bar
that shows a 100% increase.

20
10
0
–10
–20
–30
–40
–50
–60
–70
–80
–90
–100

15.4 months (95% CI, 9.6 to 18.6 months) in the interferon arm
(HR, 0.93; 95% CI, 0.73 to 1.18; P = .55). By investigator review,
the median PFS was 15.4 months (95% CI, 12.6 to 17.2 months)
in the bevacizumab arm and was 10.6 months (95% CI, 8.5
to 14.4 months) in the interferon arm (Fig 2B). Though
4.8 months longer, the difference in investigator-determined
PFS was not statistically signiﬁcant (HR, 0.90; 95% CI, 0.72 to
1.12; P = .33).
jco.org

Other Efficacy Measurements
There were no signiﬁcant differences in OS (HR, 1.16; 95%
CI, 0.88 to 1.55; P = .29). The median OS was 35.2 months (95%
CI, 33.1 to 42.8 months) in the bevacizumab arm and was not
reached on the basis of 36 months of follow-up in the interferon
arm (Fig 2C). The 12-, 24-, and 36- month survival rates for the
bevacizumab versus interferon arms were 86% versus 84%, 67%
versus 71%, and 49% versus 56%, respectively.
© 2017 by American Society of Clinical Oncology
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Table 2. Safety Analysis: CTCAE Events of Grade 3 or Higher
No. (%) of Patients

Event
Hypertension
Fatigue
Neutropenia
Proteinuria
Leukopenia
Nausea
Headache
Diarrhea
Anorexia
Abdominal pain
Elevated AST
Depression
Elevated alkaline phosphatase
Dehydration
Hyperglycemia
Lymphopenia

Bevacizumab +
Octreotide
LAR (n = 197)
62
13
0
17
2
5
9
7
1
7
1
1
2
3
2
3

(31.5)
(6.6)
(0.0)
(8.6)
(1.0)
(2.5)
(4.6)
(3.6)
(0.5)
(3.6)
(0.5)
(0.5)
(1.0)
(1.5)
(1.0)
(1.5)

IFN-a-2b +
Octreotide
LAR (n = 194)
4
50
23
1
14
9
3
9
8
5
6
7
6
5
5
5

(2.1)
(25.8)
(11.9)
(0.5)
(7.2)
(4.6)
(1.5)
(4.6)
(4.1)
(2.6)
(3.1)
(3.6)
(3.1)
(2.6)
(2.6)
(2.6)

Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; IFNa-2b, interferon alfa-2b; LAR, long-acting repeatable.

neutropenia, nausea, and diarrhea in the interferon arm. Treatment discontinuations attributed to AEs were reported in 57
patients (30%) who received bevacizumab and 47 patients (24%)
who received interferon.

Biomarkers
Baseline CGA, NSE, and 5HIAA levels were elevated in 61%,
33%, and 63% of patients, respectively. Elevated CGA was associated with shorter OS (P , .001; Fig 4A). Elevated NSE was
associated with shorter PFS by central radiology review (P = .01)
and OS (P , .001). Elevated 5HIAA was associated with shorter OS
(P = .04).
Subgroup Analyses
Of the factors considered for subgroup analysis, only biomarker 5HIAA was associated with a differential effect of bevacizumab on central review PFS. Patients with elevated 5HIAA
were less likely than those with normal 5HIAA to beneﬁt from
bevacizumab (P = .006).

DISCUSSION

TTF was signiﬁcantly longer in the bevacizumab arm (median, 9.9 months; 95% CI, 7.3 to 11.1 months) than in the interferon arm (median, 5.6 months; 95% CI, 4.3 to 6.4 months); the
HR was 0.72 (95% CI, 0.58 to 0.89; P = .003) in favor of bevacizumab (Fig 2D).
Although response rates were modest in both arms, objective
response was more common in the bevacizumab than interferon
arm (P = .008). In the bevacizumab arm, two patients (1%) had
a complete response, and 22 patients (12%) had a partial response;
in the interferon arm, there were no complete responses, and eight
patients (4%) had a partial response. Waterfall plots of the best
percentage change in target lesion measurement sums demonstrated that 65% of patients in the bevacizumab arm and 53% of
patients in the interferon arm experienced some degree of tumor
shrinkage (Fig 3).

Safety
All patients who received at least one dose of study drug were
included in safety analyses. Without adjustment for duration of
treatment, dose reductions or temporary treatment interruptions
occurred in 116 (59%) of 197 patients who received bevacizumab
and in 145 (75%) of 193 who received interferon.
AEs were consistent with the known safety proﬁles of bevacizumab and interferon. Rates of on-treatment deaths (those that
occurred during the receipt of study medication or within 30 days
of discontinuation of therapy) were similar between the treatment
arms (n = 7 [4%] in the bevacizumab arm and n = 8 [4%] in the
interferon arm).
Treatment-related AEs that occurred in at least 10% of patients are listed in Table 2. The most common were hypertension
(32%) and proteinuria (8.6%) in the bevacizumab arm and fatigue
(26.8%) and neutropenia (11.9%) in the interferon arm. The most
frequent grade 3 or 4 AEs included hypertension, proteinuria,
fatigue, and headache in the bevacizumab arm and fatigue,
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© 2017 by American Society of Clinical Oncology

Despite recent advances, there remains a signiﬁcant need for more
therapeutic options for NETs. Although no signiﬁcant differences
in PFS were observed between the bevacizumab and the interferon
arms of the SWOG S0518 study, the observed PFS for both the
bevacizumab (median, 16.6 months) and the interferon (median,
15.4 months) arms were long compared with the placebo arms of
recent phase III studies. For example, the median PFS observed
in the PROMID, RADIANT-2 (RAD001 in Advanced Neuroendocrine Tumours), and RADIANT-4 studies were 6 months,
11.3 months, and 3.9 months, respectively. 5,20,22 Only in the
CLARINET (Controlled Study of Lanreotide Antiproliferative
Response in Neuroendocrine Tumors) study, which enrolled patients with predominantly stable disease, was a longer median PFS
of 18 months observed.4
Bevacizumab did not prove to be superior to interferon in
terms of PFS. The observed median duration and Kaplan Meier
curves were similar. Ultimately, assessment of whether bevacizumab
is active in NETs would depend on the extent that interferon truly
delays progression. Given the signiﬁcant risk reduction (HR, 0.28;
95% CI, 0.16 to 0.45) previously described when octreotide plus
interferon was compared with octreotide alone, bevacizumab seems
to have activity, though it is not proven superior to interferon. This is
supported by the observation that substantial numbers of patients
experienced some degree of tumor shrinkage in both arms of the
study (65% of patients in bevacizumab arm and 53% of patients
in the interferon arm), and a higher RECIST response rate of 12%
versus 4% (P = .008) was observed in the bevacizumab arm. A
placebo control arm was not included in this study, so deﬁnitive
conclusions are not possible about the activity of bevacizumab in
NETs.
Although PFS durations were similar, a signiﬁcant difference
in TTF was observed in favor of bevacizumab. This likely is due to
differences in safety proﬁles between the two agents. Although the
most common adverse events associated with bevacizumab were
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measurement ﬁndings, such as hypertension and proteinuria,
greater than a quarter of patients in the interferon arm experienced
severe grade 3 or 4 fatigue, which may account for the greater
number patients who withdrew consent in the interferon arm.
In this analysis, we also assessed the role of CGA, NSE, and
5HIAA as biomarkers in NETs. Although the prognostic roles of
CGA and NSE have been reported in pancreatic NETs,23 their value
for NETs of nonpancreatic origin has not be been validated in
prospective clinical trials. Although NSE, elevated in 33% of patients, is not a sensitive diagnostic biomarker, this study showed
convincing evidence that both CGA (P , .001) and NSE (P , .001)
are important prognostic factors for OS. NSE was also a signiﬁcant
prognostic factor for PFS (P = .01). Earlier studies also reported
that 5HIAA was prognostic, but this study did not ﬁnd 5HIAA to be
prognostic for PFS; it did ﬁnd moderate evidence that 5HIAA is
prognostic for OS. This different result may be due, in part, to the
choice of cutoff point or to the inclusion patients who had a variety
of primary sites in which nonsecretory tumors may have a worse
prognosis.
In summary, octreotide plus bevacizumab and octreotide plus
interferon are associated with similar PFS in patients with advanced NETs. Although no improvement in PFS was observed,
bevacizumab was associated with a higher response rate, a longer
TTF, and a lower rate of fatigue than interferon.
Many advances have been made in the rapidly evolving ﬁeld of
NET since the conception of this study. These include the approval
of everolimus2 and sunitinib3 for pancreatic NETs, the approval of
lanreotide for gastroenteropancreatic NETs,4 as well as the more
recent approval of everolimus for lung and gastrointestinal
NETs.5 Whether VEGF inhibition will have a future role in NETs
that do not begin in the pancreas remains an important question
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